Predictiv
Predictiv is the building personalized Digital Twins to predict and prevent diseases and adverse drug reactions by analyzing 20,000 genes for 22,000 diseases and 750 drug reactions.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
* | N/A | Seed | |
| Total Funding | 000k | ||
Related Content
PredictivCare operates in the personalized healthcare market, offering advanced DNA testing services that analyze 20,000 genes against 22,000 diseases and 45 important medications. The company serves individuals seeking to understand their genetic predispositions and manage their health proactively. PredictivCare's business model revolves around providing comprehensive genetic insights through next-generation sequencing technology, enabling clients to access their health data anytime and share it with their care team. The company generates revenue through the sale of DNA testing kits and ongoing subscription services for health monitoring and virtual consultations. By integrating genetic data with health history, lifestyle, and behavior, PredictivCare creates a digital twin of the client to predict and prevent diseases and simulate drug responses. The company ensures compliance with privacy and security regulations to protect clients' health information. PredictivCare's services are particularly valuable for individuals at risk for conditions such as high cholesterol, heart attacks, cancer, mood disorders, acid reflux, and chronic pain.
Keywords: DNA testing, genetic insights, disease prevention, drug response simulation, personalized healthcare, next-generation sequencing, health monitoring, virtual consultations, digital twin, privacy compliance.